Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DECRYPT-BABYBRAIN: Intrathecal Topotecan and Maintenance Chemotherapy for High-risk Embryonal CNS Tumours in Children
NCT06942039Phase 1Recruiting
- Sponsor
- C17 Council
- Start
- Sep 2025
- Primary completion
- Dec 2030
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of topotecan in central nervous system embryonal tumor, sponsored by C17 Council. Primary endpoints: Feasibility of adding intrathecal (IT) topotecan and maintenance therapy after high dose chemotherapy, Feasibility of centralized diagnostics and national tumour board review for clinical management at 4 weeks and 1 more. Started Sep 2025; status: recruiting.
02
Drugs
topotecan
03
Conditions
central nervous system embryonal tumor
Beyond the preview
Go deeper on NCT06942039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06942039.